A 28-day phase 1b MAD study in participants with overweight or obesity demonstrates safety and tolerability at daily doses of 30 mg, 60 mg, and 90 mg with mean weight loss of 1.6%, 5.2%, and 5.4%, respectively, compared to 0.5% for placebo ( 2
In pregnant rats following IDA, the changes in the expressions of hepatic HAMP, FPN1, and TFR1 mRNA, as well as small intestinal FPN1 and DMT1 mRNA, and the levels of serum TF and TFR1 were further exacerbated, which is consistent with the results reported by Cornock et al
We have observed by all objective measures a significant reduction in lymphedema and the elimination of compression in the case presented as a direct result of GLP-1 RA
~ AlphaMD When it comes to optimizing hormone healthespecially testosteronemost people focus only on total testosterone levels
Bonet, J
Youll have everything you need, including on-demand provider messaging, personalized medication adjustments, and expert guidance on what to expect on your journey all as part of your membership